Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCM
Covered in this story
What has happened since
- HUTCHMED is up 4.4% since this was published, 10 days ago.
- Cytokinetics Inc is down 0.7% since this was published, 10 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $HCM yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on HUTCHMED →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.